ERT (Clario)
ERT (Clario) is recorded as a service provider in 2 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 2 of 2 trials · Latest update first
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)
Sponsor AstraZeneca AB
- Start (EU)
- Latest update
- Estimated end
eXALT3: Phase 3 Randomized Study Comparing Ensartinib to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Sponsor Xcovery Holding Co. LLC
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for ERT (Clario)?
The 2026-10-09 snapshot links ERT (Clario) to 2 distinct CTIS trials. Recorded services include Cardiac services, electronic patient-reported outcome. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for ERT (Clario)?
The most frequently recorded therapeutic areas are Solid Tumor Oncology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to ERT (Clario) conducted?
The linked trials record locations in 12 countries, including Belgium, Spain, France, Italy, Czechia. These are trial locations, not confirmed office locations or countries where ERT (Clario) delivered services.
What can this page tell me about ERT (Clario)'s trial experience?
Browse 2 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under ERT (Clario). Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- ERT (Clario)